Concurrently, it inhibits the secretion of glucagon, a hormone that increases blood glucose levels, thereby addressing hyperglycemia from both sides of the metabolic equation
Unlike melatonin, DSIP remains experimental and has much less clinical evidence supporting its use
Besides the morphine-antagonist naloxone, the central dopamine antagonist haloperidol has also been tested, presenting this peptide's close interaction with the dopamine system (11, 15-17, 19)
Dhingra L, Sangha V, Aminorroaya A, Bryde R, Gaballa A, Ali A, Mehra N, Krumholz H , Sen S, Kramer C, Martinez M, Desai M, Oikonomou E, Khera R
Injection site selection Semaglutide is administered subcutaneously, meaning into the fatty tissue just under the skin